Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Galectin Therapeutics Inc. (GALT) had Return on Tangible Equity of 6.42% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-7.58M |
|
-- |
|
-- |
|
$4.62M |
|
$-4.62M |
|
$-2.90M |
|
$-7.52M |
|
$-7.52M |
|
$-7.52M |
|
$-7.52M |
|
$-7.52M |
|
$-7.52M |
|
$-4.62M |
|
$-4.62M |
|
63.45M |
|
63.45M |
|
$-0.12 |
|
$-0.12 |
|
| Balance Sheet Financials | |
$15.43M |
|
-- |
|
$0.17M |
|
$15.60M |
|
$10.77M |
|
$120.46M |
|
$122.00M |
|
$132.77M |
|
$-119.38M |
|
$-117.17M |
|
$-117.17M |
|
64.06M |
|
| Cash Flow Statement Financials | |
$-14.29M |
|
-- |
|
$12.94M |
|
$15.12M |
|
$13.77M |
|
$-1.35M |
|
$0.97M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.43 |
|
-- |
|
-- |
|
36.60 |
|
-1.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-14.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
6.30% |
|
|
Return on Tangible Equity |
6.42% |
-48.21% |
|
-228.53% |
|
$-1.83 |
|
$-0.23 |
|
$-0.23 |
|